- Investing.com
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Neuroscience Pionee | Biogen, a leader in neurodegenerative disease therapies, faces challenges and opportunities as it navigates a complex landscape in the pharmaceutical industry |
Financial Crossroads | With a market cap of $17.45B and trading near 52-week lows, Biogen's stock shows potential value despite headwinds. Analyst price targets range from $135 to $292 |
Product Portfolio Pulse | Explore Biogen's strategy to overcome slow uptake of new drugs like Leqembi and Skyclarys, while addressing erosion in its core multiple sclerosis market |
Future Growth Catalysts | Delve into Biogen's pipeline potential, including pre-symptomatic Alzheimer's treatment, and its efforts to diversify revenue streams beyond 2026 |
Metrics to compare | BIIB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBIIBPeersSector | |
---|---|---|---|---|
P/E Ratio | 12.7x | −3.7x | −0.5x | |
PEG Ratio | 0.40 | 0.01 | 0.00 | |
Price/Book | 1.1x | 2.0x | 2.6x | |
Price / LTM Sales | 1.9x | 8.5x | 3.3x | |
Upside (Analyst Target) | 19.1% | 72.8% | 43.5% | |
Fair Value Upside | Unlock | 0.4% | 6.3% | Unlock |